Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
not available details |
| Primary information | |
|---|---|
| ID | antitb_1334, |
| Name | 855995 |
| N-Terminal modification | Cairomycin B |
| C-Terminal Modification | not available |
| Chirality | Cyclic |
| Nature | 0 |
| Source | Mix |
| Species | Natural |
| Strain | Streptomyces fungus |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC= 50 μg/mL |
| Inhibition Concentration | Both |
| Sequence | 1976 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | Swiss mice |
| Mechanism of Action | 3 mg/kg of body weight |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antimicrobial against S.aureus, B.subtilis, P.aureginosa,Pseudomonas. Antifungal also. |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1362, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | calf thymus |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 300 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1363, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | calf thymus |
| Inhibition Concentration | Mycobacterium vallée |
| In Vitro/ In vivo | Mycobacterium vallée bovine |
| Cell Line | MIC = 300 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1364, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | calf thymus |
| Inhibition Concentration | Mycobacterium R1Rv attenuated |
| In Vitro/ In vivo | Mycobacterium R1Rv attenuated human |
| Cell Line | MIC = 300 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1365, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | calf thymus |
| Inhibition Concentration | BCG-phipps attenuated |
| In Vitro/ In vivo | BCG-phipps attenuated bovine |
| Cell Line | MIC = 300 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1366, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | calf thymus |
| Inhibition Concentration | Mycobacterium H37Ra |
| In Vitro/ In vivo | Mycobacterium H37Ra avirlant Ra |
| Cell Line | MIC = 300 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1367, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | calf thymus |
| Inhibition Concentration | Mycobacterium sigerson |
| In Vitro/ In vivo | Mycobacterium sigerson avium |
| Cell Line | MIC = 300 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1368, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | calf thymus |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis Saprophyte |
| Cell Line | MIC = 300 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1369, |
| Name | 13118063 |
| N-Terminal modification | Thymus peptide |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Calf thymus |
| Inhibition Concentration | Mycobacterium tuberculii |
| In Vitro/ In vivo | Mycobacterium tuberculii BCG-Phipps |
| Cell Line | MIC = 100 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 1953 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1477, |
| Name | 25681127 |
| N-Terminal modification | Nocathiacins |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Nocardia species |
| Inhibition Concentration | Mycobacterium pneumoniae |
| In Vitro/ In vivo | Mycobacterium pneumoniae |
| Cell Line | MIC = ≤0.008 mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | McCoy cell lines |
| In vivo Model | NA |
| Lethal Dose | 0.25 μg/ml |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Bind to the 23S rRNA of the 50S ribosomal subunit and inhibit translation |
| Other activities | 23srRNA subunit of bacteria |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1479, |
| Name | 25681127 |
| N-Terminal modification | Dihydromycoplanecin A (DHMP A) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Actinoplanesawajinensis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Rv |
| Cell Line | IC50= 0.0125-25mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1480, |
| Name | 25681127 |
| N-Terminal modification | Dihydromycoplanecin A (DHMP A) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Actinoplanesawajinensis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Rv |
| Cell Line | IC90= 0.05 μg/mL |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1481, |
| Name | 25681127 |
| N-Terminal modification | Dihydromycoplanecin A (DHMP A) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Actinoplanesawajinensis |
| Inhibition Concentration | Mycobacterium intracellulare |
| In Vitro/ In vivo | Mycobacterium intracellulare |
| Cell Line | IC50= 1.56 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1482, |
| Name | 25681127 |
| N-Terminal modification | Dihydromycoplanecin A (DHMP A) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Actinoplanesawajinensis |
| Inhibition Concentration | Mycobacterium intracellulare |
| In Vitro/ In vivo | Mycobacterium intracellulare |
| Cell Line | IC90= 25 μg/mL |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1483, |
| Name | 25681127 |
| N-Terminal modification | Dihydromycoplanecin A (DHMP A) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Actinoplanesawajinensis |
| Inhibition Concentration | Mycobacteria kansaii |
| In Vitro/ In vivo | Mycobacteria kansaii |
| Cell Line | IC50= 0.39 μg/mL |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1484, |
| Name | 25681127 |
| N-Terminal modification | Dihydromycoplanecin A (DHMP A) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Actinoplanesawajinensis |
| Inhibition Concentration | Mycobacteria kansaii |
| In Vitro/ In vivo | Mycobacteria kansaii |
| Cell Line | IC90= 0.78 μg/mL |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1485, |
| Name | 25681127 |
| N-Terminal modification | Dihydromycoplanecin A (DHMP A) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Actinoplanesawajinensis |
| Inhibition Concentration | Mycobacteria smegmatis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 607 |
| Cell Line | MIC = 12.5 μg/mL |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | DHMP A + INH |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1486, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 25177 |
| Cell Line | Reduction in zone of growth to 25 mm at 100 μg conc. |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1487, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 25177 |
| Cell Line | Reduction in zone of growth to 10 mm at 25 μg |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 2.25μg/ml for M.Smegmatis ATCC 25177 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1488, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 35818 |
| Cell Line | Reduction in zone of growth to 15 mm at 100 μg |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1489, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 35818 |
| Cell Line | Reduction in zone of growth to 9 mm at 25 μg |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1490, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 25177 |
| Cell Line | Reduction in zone of growth to 30 mm at 100 μg |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 2.25 μg/ml for M.Smegmatis ATCC 25177 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1491, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 25177 |
| Cell Line | Reduction in zone of growth to 15 mm at 25 μg |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 2.25μg/ml for M.Smegmatis ATCC 25177 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1492, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 35818 |
| Cell Line | Reduction in zone of growth to 15 mm at 100 μg |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1493, |
| Name | 25681127 |
| N-Terminal modification | Pitipeptolides A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Cyanobacterium Lyngbya majuscula |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria smegmatis ATCC 35818 |
| Cell Line | Reduction in zone of growth to 10 mm at 25 μg |
| Inhibition Concentration | |
| Sequence | 2015 |
| Cytotoxicity | LoVo cancer cells |
| In vivo Model | NA |
| Lethal Dose | IC50= 1.95 μg/ml for m.Smegmatis ATCC35818 |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1494, |
| Name | 25681127 |
| N-Terminal modification | Lacticin 3147 |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Lactococcuslactis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37 Ra |
| Cell Line | IC90= 7.5 mg/ml (±0.36) |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1495, |
| Name | 25681127 |
| N-Terminal modification | Lacticin 3148 |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Lactococcuslactis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria kansasii CIT11/06 |
| Cell Line | IC90= 60 mg/ml (±0.75) |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1496, |
| Name | 25681127 |
| N-Terminal modification | Lacticin 3149 |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Lactococcuslactis |
| Inhibition Concentration | Mycobacterium avium |
| In Vitro/ In vivo | Mycobacterium avium subspecies paratuberculosis ATCC 19698 |
| Cell Line | IC90= 15mg/ml (±0.30) |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1497, |
| Name | 25681127 |
| N-Terminal modification | Nisin A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Lactococcus lactis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37 Ra |
| Cell Line | IC90= >60mg/ml (±0.18) |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1498, |
| Name | 25681127 |
| N-Terminal modification | Nisin A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Lactococcuslactis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacteria kansasii CIT11/06 |
| Cell Line | IC90= 60 mg/ml (±0.13) |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1499, |
| Name | 25681127 |
| N-Terminal modification | Nisin A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Lactococcuslactis |
| Inhibition Concentration | Mycobacterium avium |
| In Vitro/ In vivo | Mycobacterium avium subspecies paratuberculosis ATCC 19698 |
| Cell Line | IC90= >60 mg/ml (± 2.02) |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit biosynthesis of peptidoglycan and form pores in bacterial membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1500, |
| Name | 25681127 |
| N-Terminal modification | Sansanmycins A (Ssa) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Streptomyces species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | IC50= 16 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit the MraY translocase present in the bacterial cell membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1501, |
| Name | 25681127 |
| N-Terminal modification | Sansanmycins A (Ssa) |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Streptomyces species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis 2199 |
| Cell Line | IC50= 32 μg/ml |
| Inhibition Concentration | In vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit the MraY translocase present in the bacterial cell membrane |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1502, |
| Name | 25681127 |
| N-Terminal modification | Cyclomarin A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Streptomyces species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | IC50= 0.3mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | |
| Combination Therapy | Change the clp1subunit of casinolytic protease by allosteric binding |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1503, |
| Name | 25681127 |
| N-Terminal modification | Massetolide A |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Pseudomonas fluorescens SS101 |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis h37RV |
| Cell Line | MIC = 5 mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | |
| Combination Therapy | interfere with bacterial cell wall biosynthesis |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1504, |
| Name | 25681127 |
| N-Terminal modification | Visconsin |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Pseudomonas species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium avium intercellularae |
| Cell Line | MIC = 10 mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | |
| Combination Therapy | interfere with bacterial cell wall biosynthesis |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1505, |
| Name | 25681127 |
| N-Terminal modification | Bacitracin |
| C-Terminal Modification | not available |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Bacillus subtilis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 130mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | inhibit bacterial cell wall synthesis |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against E.coli, S.aureus, bacillus, pseudomonas |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1514, |
| Name | 25681127 |
| N-Terminal modification | Hirsutatins A |
| C-Terminal Modification | not available |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Hirsutellanivea |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC =50 mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1515, |
| Name | 25681127 |
| N-Terminal modification | Hirsutatins B |
| C-Terminal Modification | not available |
| Chemical Modification | Free |
| Linear/Cyclic | Free |
| Length | None |
| Chirality | Branched cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from Hirsutellanivea |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = 50 mg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2015 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1654, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacteria smegmatis |
| In Vitro/ In vivo | Mycobacteria smegmatis (aerobic) |
| Cell Line | IC90= 0.1 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1655, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A1 |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium bovis BCG |
| In Vitro/ In vivo | Mycobacterium bovis BCG (aerobic) |
| Cell Line | IC90= 1.56 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1656, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins B |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv (aerobic) |
| Cell Line | IC90= 0.63 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1657, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacteria smegmatis |
| In Vitro/ In vivo | Mycobacteria smegmatis (hypoxic) |
| Cell Line | IC90= 0.1 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1658, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A1 |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium bovis BCG |
| In Vitro/ In vivo | Mycobacterium bovis BCG (hypoxic) |
| Cell Line | IC90= 1.56 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1659, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins B |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv (hypoxic) |
| Cell Line | IC90= 0.63 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1660, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacteria smegmatis |
| In Vitro/ In vivo | Mycobacteria smegmatis (aerobic) |
| Cell Line | IC90= 0.02 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1661, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A1 |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium bovis BCG |
| In Vitro/ In vivo | Mycobacterium bovis BCG (aerobic) |
| Cell Line | IC90= 0.16 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1662, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins B |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv (aerobic) |
| Cell Line | IC90= 0.02 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1663, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacteria smegmatis |
| In Vitro/ In vivo | Mycobacteria smegmatis (hypoxic) |
| Cell Line | IC90= 0.02 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1664, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A1 |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium bovis BCG |
| In Vitro/ In vivo | Mycobacterium bovis BCG (hypoxic) |
| Cell Line | IC90= 0.16 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1665, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins B |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv (hypoxic) |
| Cell Line | IC90= 0.02 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1666, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacteria smegmatis |
| In Vitro/ In vivo | Mycobacteria smegmatis (aerobic) |
| Cell Line | IC90= 0.12 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1667, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A1 |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium bovis BCG |
| In Vitro/ In vivo | Mycobacterium bovis BCG (aerobic) |
| Cell Line | IC90= 2.0 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1668, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins B |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv (aerobic) |
| Cell Line | IC90= 0.13 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1669, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacteria smegmatis |
| In Vitro/ In vivo | Mycobacteria smegmatis (hypoxic) |
| Cell Line | IC90= 0.12 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1670, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins A1 |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium bovis BCG |
| In Vitro/ In vivo | Mycobacterium bovis BCG (hypoxic) |
| Cell Line | IC90= 2.0 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1671, |
| Name | 20483615 |
| N-Terminal modification | Trichoderins B |
| C-Terminal Modification | not available |
| Nature | 0 |
| Species | Natural |
| Strain | Trichoderma species |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv (hypoxic) |
| Cell Line | IC90= 0.13 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 2010 |
| Cytotoxicity | Human THP-1 cell lines |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1677, |
| Name | 353012 |
| N-Terminal modification | Globomycin |
| C-Terminal Modification | not available |
| Chirality | Cyclic |
| Nature | 0 |
| Source | D |
| Origin | Cationic |
| Species | Natural |
| Strain | Derived from streptomyces halstedii 13912 |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC607 |
| Cell Line | MIC = >100 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1977 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against bacillus sub!ills , E.coli, S.aureus Antifungal against Aspergillus oryzae SANK 11262, Candida albicans |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1678, |
| Name | 950316 |
| N-Terminal modification | Samarosporin |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Inhibition Concentration | Mycobacterium |
| In Vitro/ In vivo | Mycobacterium 607 |
| Cell Line | MIC = 15.6 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1976 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Staphylococcus aureus FDA 209 P, Staphylococcus albus, Corynebacterium sepedonicum,Sarcina lutea,Bacillus subtilis PCI 219,Micrococcus flavus,Serratia marcescens,Aerobacter aerogenes,Escherichia coli,Salmonella enteritidis No. 11, Shigella flexneri,Erwinia carotovora,Xanthomonas oryzae and Antifungal Candida albicans YU-1200 Cryptococcus neoformans Saccharomyces sake Trichophyton interdigitale Sporotricum gougeroti Penicillium chrysogenum |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1679, |
| Name | 1112764 |
| N-Terminal modification | TL-119 |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Bacillus species, strain TL-119 |
| Inhibition Concentration | Mycobacterium Tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = >50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1974 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Bacillus subtilis PCI 219, Staphylococcus aureus FDA 209P JC-1, Staphylococcus aureus Smith, Diplococcus pneumoniae type I, Streptococcus pyogenes C-203, Escherichia coli NIHJ JC-2, Klebsiella pneumoniae, Salmonella typhimurium, Pseudomonas aeruginosa Ps 24 |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1680, |
| Name | 1112765 |
| N-Terminal modification | 61-26 |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Origin | Weakly basic |
| Species | Natural |
| Strain | Bacillus, strain 61-26, |
| Inhibition Concentration | Mycobacterium Tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis H37Rv |
| Cell Line | MIC = >50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1974 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Bacillus subtilis PCI 219, Bacillus anthracis, Staphylococcus aureus FDA 209P JC-1, Staphylococcus aureus Smith, Diplococcus pneumoniae type I, Streptococcus pyogenes C-203, Escherichia coli NIHJ JC-2, Klebsiella pneumoniae, Salmonella typhimurium And Antifungal against Candida albicans M-9, Trichophyton rubrum, Trichophyton mentagrophytes |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1681, |
| Name | 1184471 |
| N-Terminal modification | KM-8 |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptoverticillium |
| Inhibition Concentration | M. smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC 607 |
| Cell Line | MIC = 100 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Staphylococcus aureus FDA 209 P, Sarcina lutea PCI 1001, Bacillus subtilis PCI 219, Bacillus cereus var. mycoides, Bacillus agri, Bacillus anthracis, Corynebacterium paurometabolurn, Escherichia coli NIHJ, Klebsiella pneumoniae PCI 602, Shigella flexneri, Xanthomonas oryzae Antifungal Candida albicans, Aspergillus niger, Alternaria kikuchiana, Botrytis cinerea |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1682, |
| Name | 4630599 |
| N-Terminal modification | Cryomycin |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Origin | Weakly acidic |
| Species | Natural |
| Strain | Streptomyces griseus subsp. psychrophilus, |
| Inhibition Concentration | Mycobacterium avium |
| In Vitro/ In vivo | Mycobacterium avium IFO 3 |
| Cell Line | MIC = 20 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1972 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against bacillus megaterium, E.coli, P.aeuroginosaand S.aureus,Antifungal Aspergillus niger, Mucor racemosus , Penicillium chrysogenum, Neurospora crassa |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1683, |
| Name | 4630599 |
| N-Terminal modification | S35-Siomycin |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces sioyaensis |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis |
| Inhibition Concentration | in vitro |
| Sequence | 1972 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | many clinical resistant strains of Staphylococcus |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1684, |
| Name | 5042449 |
| N-Terminal modification | Jolipeptin |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Bacillus polymyxa var. colistinus Koyama |
| Inhibition Concentration | Mycobacterium Tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis 607 |
| Cell Line | MIC = 10 μg/mL |
| Inhibition Concentration | in vitro |
| Sequence | 1972 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against E. coli B, E. coli NIHJ, Staphylococcus aureus FDA 209P, Bacillus subtilis PCI 219, Micrococcus lysodeihticus |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1685, |
| Name | 5459623 |
| N-Terminal modification | S-520 |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces diastaticus |
| Inhibition Concentration | Mycobacterium Tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis 607 |
| Cell Line | MIC = 100 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1970 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Bacillus subtilis, Bacillus anthracis, Staphylococcus aureus, Staphylococcus aureus,Streptococcus pyogenes,Diplococcus pneumoniae, Sarcinalutea Corynebacterium diphtheriae |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1686, |
| Name | 5459623 |
| N-Terminal modification | S-520 |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces diastaticus |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis |
| Cell Line | MIC = 10 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1970 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Bacillus subtilis, Bacillus anthracis, Staphylococcus aureus, Staphylococcus aureus,Streptococcus pyogenes,Diplococcus pneumoniae, Sarcinalutea Corynebacterium diphtheriae |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1687, |
| Name | 5459623 |
| N-Terminal modification | S-520 |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces diastaticus |
| Inhibition Concentration | Mycobacterium phlei |
| In Vitro/ In vivo | Mycobacterium phlei |
| Cell Line | MIC = 5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1970 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Bacillus subtilis, Bacillus anthracis, Staphylococcus aureus, Staphylococcus aureus,Streptococcus pyogenes,Diplococcus pneumoniae, Sarcinalutea Corynebacterium diphtheriae |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1688, |
| Name | 5723086 |
| N-Terminal modification | Pepthiomycin A |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces roseospinusx |
| Inhibition Concentration | Mycobacterium |
| In Vitro/ In vivo | Mycobacterium 607 |
| Cell Line | MIC = >100 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1968 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Staphylococus aureus,arcina ltea etc Antifungal against Aspergillus niger |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1689, |
| Name | 5723086 |
| N-Terminal modification | Pepthiomycin B |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces roseospinusx |
| Inhibition Concentration | Mycobacterium |
| In Vitro/ In vivo | Mycobacterium 607 |
| Cell Line | MIC = >50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1968 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Staphylococus aureus,arcina ltea etc Antifungal against Aspergillus niger |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1690, |
| Name | 6432761 |
| N-Terminal modification | Myxovalargins |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Myxobacterium Myxococcus fulvus strain Mx f65. |
| Inhibition Concentration | Mycobacterium |
| In Vitro/ In vivo | Mycobacterium phlei |
| Inhibition Concentration | in vitro |
| Sequence | 1982 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antibacterial against Corynebacterium mediolanum, Bacillus megaterium, Bacillus subtilis, Staphylococcus aureus, Brevibacterium ammoniagenes, Arthrobacter simplex, Arthrobacter rubellus, Micrococcus lysodeikticus, Micrococcus luteus, Nocardia (lava), Nocardia corallina, Rhizobium 1-595, Rhizobium meliloti, Myxococcus fulvus Mx f65, Myxococcus fulvus Mx f65-M9, Salmonella typhimurium, Escherichia coli, Klebsiella sp., Serratia marcescens, Pseudomonas fluorescens,Pseudomonas aeruginosa, Pseudomona |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1691, |
| Name | 6732903 |
| N-Terminal modification | Takaokamycin |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces sp. AC-1978, |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC 607 |
| Cell Line | MIC = >100 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1984 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Staphylococcus aureus ATCC 6538P, S. aureus FDA 209P, Bacillus subtilis ATCC 6633, B. cereus IFO 3001, Micrococcus luteus ATCC 9341, Escherichia coli NIHJ, E. coli NIHJ JC-2, Klebsiella pneumoniae ATCC 10031, Proteus vulgaris IFO 3167, Pseudomonas aeruginosa IFO 3080 |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1692, |
| Name | 28292 |
| N-Terminal modification | Tuberactinamine N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC 607 |
| Cell Line | MIC = 12.5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1693, |
| Name | 28292 |
| N-Terminal modification | Tuberactinomycin N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis ATCC 607 |
| Cell Line | MIC = 12.5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1694, |
| Name | 28292 |
| N-Terminal modification | Tuberactinamine N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | Reduction in CFU at 12.5 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1695, |
| Name | 28292 |
| N-Terminal modification | Tuberactinomycin N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | Reduction in CFU 25μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1696, |
| Name | 28292 |
| N-Terminal modification | Tuberactinamine N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | Reduction in CFU at 25 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1697, |
| Name | 28292 |
| N-Terminal modification | Tuberactinomycin N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | Reduction in CFU at 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1698, |
| Name | 28292 |
| N-Terminal modification | Tuberactinamine N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | MIC = 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1699, |
| Name | 28292 |
| N-Terminal modification | Tuberactinomycin N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | MIC = 100 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1700, |
| Name | 28292 |
| N-Terminal modification | Tuberactinamine N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | MIC = 100 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1701, |
| Name | 28292 |
| N-Terminal modification | Tuberactinamine N |
| C-Terminal Modification | not available |
| Length | None |
| Nature | 0 |
| Species | Natural |
| Strain | Streptomyces griseoverticillatus var. tuberacticus |
| Inhibition Concentration | Mycobacterium bovis |
| In Vitro/ In vivo | Mycobacterium bovis BCG |
| Cell Line | MIC = 6.3 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1975 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Bactericidal against corneybacterium diptheriae, bacillus subtilis, E.coli, Salmonellatyphosa, klebsiella pneumoniare,proteus vulgaris |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1705, |
| Name | 8641802 |
| N-Terminal modification | Synthetic rabbit neytrophil (SNP-1) |
| C-Terminal Modification | not available |
| Nature | 0 |
| Origin | Cationic |
| Species | Natural |
| Strain | Rabbit neutrophil |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Ra 7632G |
| Cell Line | 5Reduction in CFU at 0 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1706, |
| Name | 8641802 |
| N-Terminal modification | Synthetic rabbit neytrophil (SNP-1) |
| C-Terminal Modification | not available |
| Nature | 0 |
| Origin | Cationic |
| Species | Natural |
| Strain | Rabbit neutrophil |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Ra 9034G |
| Cell Line | Reduction in CFU at 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1707, |
| Name | 8641802 |
| N-Terminal modification | Synthetic rabbit neytrophil (SNP-1) |
| C-Terminal Modification | not available |
| Nature | 0 |
| Origin | Cationic |
| Species | Natural |
| Strain | Rabbit neutrophil |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis Ra 11170G |
| Cell Line | Reduction in CFU at 50 μg/ml |
| Inhibition Concentration | in vitro |
| Sequence | 1996 |
| Cytotoxicity | NA |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Microbial membrane disruption |
| Other activities | NA |
| PMID | NA |
| Year of Publication | NA |
| Tertiary Structure (Technique) | Not Predicted), |